Table 3 Association between nailfold videocapillaroscopy patterns and disease characteristics of patients with systemic sclerosis included in the discovery cohort
From: Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis
NVC pattern | P value | Multiple linear regression (r) | P value | ||
|---|---|---|---|---|---|
Early/active (n= 36) | Late (n= 24) | ||||
Age, median (range) | 58 | 53 | 0.2 | ||
Females, n (%) | 27 (75) | 19 | 0.9 | ||
Disease duration, median (range) | 9.91 | 7.20 | 0.2 | ||
Diffuse cutaneous subset, n (%) | 13 (36) | 11 (46) | 0.9 | ||
Modified Rodnan skin score > 14, n (%) | 6 (17) | 13 (54) | 0.005* | 0.42 | 0.0008 |
History of digital ulcers, n (%) | 13 (36) | 16 (67) | 0.03* | 0.25 | 0.03 |
Pulmonary fibrosis, n (%) | 15 (42) | 13 (54) | 0.5 | ||
Pulmonary arterial hypertension on RHC, n (%) | 2 (6) | 2 (8) | 0.9 | ||
Positive antitopoisomerase antibodies, n (%) | 12 (33) | 16 (67) | 0.02* | ||
Positive anticentromere antibodies, n (%) | 9 (25) | 3 (13) | 0.4 | ||
FVC < 75, n (%) | 5 (14) | 8 (33) | 0.1* | 0.29 | 0.01 |
DLCO/VA < 75%, n (%) | 9 (25) | 14 (58) | 0.02* | ||
Treatment with angiotensin-converting enzyme inhibitors, n (%) | 8 (22) | 11 (46) | 0.09* | ||
Treatment with endothelin-receptor antagonists and/or PDE5 inhibitors, n (%) | 4 (11) | 8 (33) | 0.08* | ||